Page 5 - Solid Biosciences News Today

- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, ...

TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 8:50ET Fed's Cook speaks; 9:45ET S&P Global US Manufacturing PMI, Composite PMI; 1:00ET Fed's Daly and Kashkari speak TODAY’S HIGHLIGHTS: Migrant encounters at US-Mexico border on pace to reach record highs in SeptemberChina climate envoy says phasing out fossil fuels 'unrealistic' China and

– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases –BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote...

Stoke Therapeutics, Inc. announced the appointment of Ian Smith to its Board of Directors effective September 19. Ian F. Smith is a director of Stoke Therapeutics. He serves as a Senior Advisor to...

– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – ...

Great Point Partners LLC acquired a new stake in shares of Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 210,405 shares of the company’s stock, valued at approximately $997,000. Great Point Partners LLC owned […]

Lili Clark of Lyda Hill Philanthropies and LH Capital, Gabby Everett of BioLabs, and Claire Aldridge of Form Bio—a spin out of Colossal—talk about the state of the industry, advancements, and future forecast.

Lili Clark of Lyda Hill Philanthropies and LH Capital, Gabby Everett of BioLabs, and Claire Aldridge of Form Bio—Colossal's bioinformatics arm—talk about the state of the industry, advancements, and future forecast.

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Stock analysts at Leerink Partnrs boosted their Q3 2023 earnings per share (EPS) estimates for shares of Solid Biosciences in a report released on Wednesday, August 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($1.05) for the quarter, […]

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Equities research analysts at Leerink Partnrs raised their Q3 2023 earnings per share (EPS) estimates for Solid Biosciences in a research note issued to investors on Wednesday, August 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($1.05) per share for […]